Neurology · 2019 · 16 citations · 0 references
Life SciencesImmunologyNeurologyClinical NeuroscienceInflammationNeuroimmunologyBiomarkers Of NeurodegenerationCerebrospinal Fluid BiomarkersCerebrospinal Fluid ImmunologyMultiple SclerosisMultiple Sclerosis PharmacotherapyNeuroinflammationAxonal Damage BiomarkersAxonal Injury BiomarkersCerebrospinal Fluid Inflammatory BiomarkersLumbar Puncture AdministrationMultiple Sclerosis TherapyNeurofilament ProteinsOcrelizumab TherapyRelapsing-remitting Multiple Sclerosis Treatment
To provide interim analysis (IA) results from the relapsing multiple sclerosis (RMS) cohort of OBOE (Ocrelizumab Biomarker Outcome Evaluation; NCT02688985), a cerebrospinal fluid (CSF) and blood biomarker study.